- Home
- TYGO vs ADAG Comparison
TYGO vs ADAG Comparison
Compare TYGO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- ADAG
- Stock Information
- Founded
- TYGO 2007
- ADAG 2011
- Country
- TYGO United States
- ADAG China
- Employees
- TYGO N/A
- ADAG N/A
- Industry
- TYGO Semiconductors
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- ADAG Health Care
- Exchange
- TYGO Nasdaq
- ADAG Nasdaq
- Market Cap
- TYGO 82.5M
- ADAG 90.8M
- IPO Year
- TYGO N/A
- ADAG 2021
- Fundamental
- Price
- TYGO $1.25
- ADAG $1.69
- Analyst Decision
- TYGO Strong Buy
- ADAG Strong Buy
- Analyst Count
- TYGO 2
- ADAG 2
- Target Price
- TYGO $5.25
- ADAG $7.00
- AVG Volume (30 Days)
- TYGO 2.7M
- ADAG 75.8K
- Earning Date
- TYGO 07-29-2025
- ADAG 08-12-2025
- Dividend Yield
- TYGO N/A
- ADAG N/A
- EPS Growth
- TYGO N/A
- ADAG N/A
- EPS
- TYGO N/A
- ADAG N/A
- Revenue
- TYGO $74,405,000.00
- ADAG $103,204.00
- Revenue This Year
- TYGO $69.44
- ADAG $9,289.17
- Revenue Next Year
- TYGO $21.75
- ADAG $36.84
- P/E Ratio
- TYGO N/A
- ADAG N/A
- Revenue Growth
- TYGO 52.31
- ADAG N/A
- 52 Week Low
- TYGO $0.58
- ADAG $1.33
- 52 Week High
- TYGO $1.80
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- TYGO 48.09
- ADAG 43.13
- Support Level
- TYGO $1.21
- ADAG $1.65
- Resistance Level
- TYGO $1.37
- ADAG $2.54
- Average True Range (ATR)
- TYGO 0.12
- ADAG 0.31
- MACD
- TYGO -0.01
- ADAG -0.04
- Stochastic Oscillator
- TYGO 10.71
- ADAG 4.21
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.